Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + HMA + LDAC in R/R or MRD+ AML
NCT05362942Phase 2Unknown
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- May 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Complete Remission Rate, Complete Minimal Residual Disease Response Rate and 1 more. Status: unknown.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05362942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05362942.